Gemcitabine plus S-1 (GS) prolonged progression-free survival (PFS) and greatly improved objective response rate (ORR) as well as disease control rate (DCR) of Asian patients with locally advanced and metastatic pancreatic cancer (PC). However, limited data of GS regimen exist on the efficacy and safety in the treatment of Chinese patients with advanced PC. To assess the efficacy and safety of gemcitabine plus S-1 (GS regimen) as the first-line chemotherapy in Chinese patients with advanced PC, we designed this prospective study.
Study Type
OBSERVATIONAL
Enrollment
96
Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer
First affiliated hospital, Zhejiang University
Hangzhou, Zhejiang, China
Progression-free survival
the time from the beginning of chemotherapy to the date of disease progression or death from any cause.
Time frame: 2014-01-01 to 2017-12-31
Overall survival
the time from the beginning of chemotherapy to the date of death from any cause.
Time frame: 2014-01-01 to 2017-12-31
Objective response rate
the percentage of patients with CR or PR
Time frame: 2014-01-01 to 2017-12-31
adverse events
Time frame: 2014-01-01 to 2017-12-31
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.